- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06389539
Synbiotic to Attenuate Resorption of the Skeleton (STARS)
A Randomized, Double-Blind, Placebo-Controlled, Clinical Food Trial of Probiotic/Prebiotic Medical Food for the Dietary Management of Age Related Bone Loss
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
There are currently no consistent guidelines on how middle aged and older adults can maintain healthy bone mass as they age. Hence, there is an unmet need for safe and effective dietary interventions for the metabolic processes underlying bone loss. The objective of this project, is to test the efficacy of a probiotic/prebiotic combination or synbiotic i.e. Solarea Bio defined microbial assemblage 111 (SBD111) medical food on the skeleton of older women.
Aim 1: To determine the effect of 18 months of daily intake of SBD111 medical food on the primary outcome of lumbar spine dual energy x-ray absorptiometry (DXA) bone mineral density (BMD) and secondary outcomes (Biomechanical Computed Tomography analysis (BCT)-derived vertebral compressive strength, volumetric BMD (vBMD), and markers of bone turnover) in women.
Hypothesis 1a: BMD, vertebral compressive strength, and vBMD will be greater in women randomized to SBD111 medical food compared to placebo.
Hypothesis 1b: Biochemical markers of bone turnover will decrease with SBD111 medical food use compared to placebo.
Aim 2: To determine the effect of 18 months of daily intake of SBD111 medical food on markers of inflammation and gut microbiome function (secondary outcomes) in women.
Hypothesis 2a: Markers of inflammation [interleukin 17A (IL17A) and tumor necrosis factor alpha (TNF-α)] will be reduced with SBD111 medical food use compared to placebo.
Hypothesis 2b: Functional genes and pathways related to fiber breakdown (glycosyl hydrolases), menaquinone 7 production, and short chain fatty acid (SCFA) production, will be enriched in stool metagenomes and upregulated in stool metatranscriptomes from those receiving SBD111 medical food compared to placebo.
Eligible women will be randomized to SBD111 medical food versus placebo capsules for 18 months. Assessments will be made at the in-person baseline visit, 9-month and 18-month follow-up visits as well as monthly telephone calls.
The primary outcome is lumbar spine BMD (g/cm2) and secondary outcomes include vertebral compressive strength (N), vBMD (g/cm3), and bone biomarkers.
Intent-to-treat analysis will be conducted for all endpoints.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Shivani Sahni, PhD
- Phone Number: 617-971-5382
- Email: ShivaniSahni@hsl.harvard.edu
Study Contact Backup
- Name: Evelyn O'Neill
- Phone Number: 617-697-6599
- Email: oneill@hsl.harvard.edu
Study Locations
-
-
Massachusetts
-
Roslindale, Massachusetts, United States, 02131
- Hebrew SeniorLife
-
Contact:
- Kathryn Tasker
- Phone Number: 617-971-5351
- Email: KathyTasker@hsl.harvard.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Provide written informed consent
- Stated availability throughout entire study period and willingness to fulfill all details of the protocol
- Age 60 years and above
- DXA-BMD of the hip and spine (T-score) > -2.5
- 25-hydroxy vitamin D ≥ 20 ng/mL
- Normal renal function (eGFR >50 ml/min)
- Willing to comply with protocol and report on compliance and side effects during study period.
Exclusion Criteria:
- BMI greater than equal to 35 kg/m2.
- Participants consuming dietary supplements (fish oil, probiotics/prebiotics, and fiber) in the prior month, and and unwilling to avoid these supplements for the duration of the study.
- Known or suspected allergies to probiotics, gelatin, rice, edible fruit extract or berries.
- We will exclude women using antibiotics in the past 3 months but those placed on an antibiotic after enrollment, will be retained.
- History of drug and/or alcohol abuse at the time of enrolment.
Presence of any of the following:
- History of other bone disorders (e.g. Paget's disease)
- History of major low-trauma fragility fractures (hip, forearm, humerus, spine) since the age of 50 years
- History of cancer other than skin cancer <5 years in remission, autoimmune disease, immune problems such as AIDS, type 2 diabetes, gastrointestinal disorders (ulcerative colitis, inflammatory bowel disease)
- History of colon resection, any disease that could interfere with the intestinal barrier function such as ulcerative colitis, irritable bowel syndrome or Crohn's disease
- Women with untreated hyperparathyroidism
- History of chronic antibiotic use
- History of bariatric surgery
- History of partial colectomy
- History of problems with pancreas
- History of history of chronic Hepatitis B or Hepatitis C, cirrhosis, fatty liver (nonalcoholic steatohepatitis; NASH) or chronic liver disease
- History of problems with your heart valves, endocarditis, or previously had a valve replacement
- Current have problems with bone marrow such as myelodysplastic syndrome or anemia requiring transfusions
- Women with spine abnormalities that would interfere with the assessment of BMD
- Current smoking or use of nicotine products within the past 6-months
- Major surgery or endoscopy within last 3 months
- Coloscopy planned in the next 18-months and unwilling to reschedule it
- Indwelling catheter, implanted hardware/prosthetic device or feeding tube
- Any medical condition that could interfere with the conduct of the study
- Treatment with calcitonin, estrogens, selective estrogen receptor modulators, progestins, anabolic steroids, or glucocorticoids in the past 6 months
- Treatment with bisphosphonates in the past 3 yrs
- Previous treatment with parathyroid hormone (PTH), abaloparatide, romosozumab or denosumab in the last year or current coumadin use.
- Participation in other bone, diet, autoimmune, or GI related clinical trials in the last 6 months. If the subject has been in a recent experimental trial, these must have been completed not less than 60 days prior to this study.
- Participants who plan on changing diet and/or exercise regime during trial participation.
Screening laboratory tests greater than upper normal limit (ULN) or less than lower normal limit (LLN):
- 25-hydroxy vitamin D <20 ng/mL
- Renal dysfunction (eGFR ≤50 ml/min)
- Seated blood pressure greater than equal to 160 mm Hg or seated diastolic BP greater than equal to 100mm Hg.
- Short Blessed Test score >10 or judged by the research staff as unable to follow the study protocol
- Any other condition that in the opinion of the investigator or study clinician would jeopardize the safety or rights of the volunteer participating in the study or would make it unlikely the volunteer could complete the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SBD111 medical food
This group will receive SBD111 medical food capsules to be consumed over 18 months.
|
SBD111 medical food is a defined microbial assemblage (DMA) consisting of oligofructose and dried berry powder (prebiotics), a Pseudomonas fluorescens, a Lactobacillus brevis, a Leuconostoc mesenteroides, a Lactobacillus plantarum, and a Pichia kudriavzevii (yeast).
|
Placebo Comparator: Placebo
This group will receive placebo capsules to be consumed over 18 months.
|
Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lumbar spine BMD (g/cm2)
Time Frame: Change over 18 months
|
BMD of the lumbar spine (L1-L4) will be measured at the baseline exam, 9-month, and 18-month final follow-up visit
|
Change over 18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vertebral compressive strength (N)
Time Frame: Change over 18 months
|
Quantitative computed tomography (QCT) scans acquired at baseline and 18-months will be used to estimate vertebral compressive bone strength using Biomechanical Computed Tomography (BCT, VirtuOst, O.N. Diagnostics, Berkeley, CA).
|
Change over 18 months
|
volumetric BMD
Time Frame: Change over 18 months
|
Measurements of integral and vertebral trabecular vBMD at L1-L3.
|
Change over 18 months
|
C-terminal cross-linked telopeptide of type I collagen (β-CTX)
Time Frame: Change over 18 months
|
A biochemical marker of bone resorption
|
Change over 18 months
|
Procollagen Type I Intact N-terminal Propeptide (P1NP)
Time Frame: Change over 18 months
|
A biochemical marker of bone formation
|
Change over 18 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Shivani Sahni, PhD, Hebrew SeniorLife
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00070958
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammation
-
University of EdinburghUmeå UniversityCompletedSystemic Inflammation | Respiratory InflammationSweden
-
University of AarhusAarhus University Hospital; University of CopenhagenCompletedSystemic Inflammation | Airway InflammationDenmark
-
Sykehuset TelemarkRikshospitalet University Hospital; Helse Sor-OstCompletedAirway Inflammation | Peripheral Blood Inflammation Markers | Cement Dust ExposureNorway
-
Assistance Publique - Hôpitaux de ParisCompletedDigestive InflammationFrance
-
Pamukkale UniversityCompletedPeriodontal InflammationTurkey
-
Universidade Federal do ParaCompleted
-
KLE Society's Institute of Dental SciencesCompletedRegenerative InflammationIndia
-
Fondation Ophtalmologique Adolphe de RothschildCompleted
-
Oral Science International Inc.AdvarraNot yet recruiting
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States